CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Go back to CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies| (NASDAQ: CRSP) | Delayed: 56.56 -0.77 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.33 | 52 Week High | $18.88 | |||
| Open | $58.00 | 52 Week Low | $13.75 | |||
| Day High | $59.34 | P/E | N/A | |||
| Day Low | $55.63 | EPS | $0.00 | |||
| Volume | 3,382,444 | |||||
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 508.34 -8 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $516.34 | 52 Week High | $134.71 | |||
| Open | $516.34 | 52 Week Low | $73.31 | |||
| Day High | $518.10 | P/E | N/A | |||
| Day Low | $505.01 | EPS | $-1.98 | |||
| Volume | 2,434,829 | |||||
